| アブストラクト | Background: Guidelines for the management of dyslipidemias recommend intensive low-density lipoprotein (LDL-C) control through lifestyle advice and lipid-lowering drugs to reduce the risk of cardiovascular disease (CVD). Objective: This retrospective study aimed to characterize the adult primary care population with primary hypercholesterolemia (PH)/mixed dyslipidemia (MD). Methods: Data on adults with PH/MD between 1 January 2009 and 31 December 2019 in the UK were extracted from linked primary Clinical Practice Research Datalink (CPRD) and secondary care (Hospital Episode Statistics) datasets and analyzed. Results: A total of 279,221 patients met the inclusion criteria. Mean follow-up was 8.6 years. Crude prevalence of PH/MD increased from 13.5% in 2009 to 23.5% by 2019. The incidence decreased from 176 to 49 per 100,000 population. Mean age of the cohort was 58 years, baseline LDL-C was 4.32 mmol/L, 19.6% had atherosclerotic CVD, 30.1% diabetes, and 8.5% heterozygous familial hypercholesterolemia. Estimated LDL-C reductions of 40% and 50% were achieved in 2.6% and 2.3% of patients, respectively. Most received moderate-intensity statins as monotherapy (62.4%); high-intensity statins were used less frequently (24.3% as initial treatment). Less than 10% of patients received ezetimibe plus statins of different intensities. Conclusion: The prevalence of dyslipidemia doubled between 2009 and 2019, likely due to more systematic identification of PH/MD. A large proportion of patients with PH/MD are of high and very high CV risk, remain suboptimally treated in terms of lipid lowering, and may experience CV events with associated non-negligible clinical and economic sequelae. Despite intensive LDL-C-lowering recommendations, these do not translate in clinical practice to the wider population. |
|---|
| ジャーナル名 | ClinicoEconomics and outcomes research : CEOR |
|---|
| Pubmed追加日 | 2022/4/13 |
|---|
| 投稿者 | Bilitou, Aikaterini; Were, John; Farrer, Archie; Rabe, Adrian; Ming, Simon Wan Yau; Haq, Inaam; Dunton, Kyle |
|---|
| 組織名 | Daiichi Sankyo Europe GmbH, Munich, Bayern, Germany.;Health iQ Ltd, London, UK.;Imperial College London, London, UK.;Daiichi Sankyo UK Ltd, Uxbridge Business Park, Uxbridge, UK. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/35411162/ |
|---|
